Eric H Au1,2,3, Jeremy R Chapman3, Jonathan C Craig4, Wai H Lim5, Armando Teixeira-Pinto6,2, Shahid Ullah7,8, Stephen McDonald7,8, Germaine Wong6,2,3. 1. School of Public Health, University of Sydney, Sydney, Australia; e.au@sydney.edu.au. 2. Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia. 3. Centre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia. 4. College of Medicine and Public Health, Flinders University, Adelaide, Australia. 5. Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Australia. 6. School of Public Health, University of Sydney, Sydney, Australia. 7. Australia and New Zealand Dialysis and Transplant Registry, South Australian Health and Medical Research Institute, Adelaide, Australia; and. 8. Adelaide Medical School, University of Adelaide, Adelaide, Australia.
Abstract
Background Patients with ESRD have a substantially increased cancer risk, but few studies have examined the patterns of cancer mortality along a patient's journey from dialysis to transplantation. METHODS: We identified all Australian patients on dialysis and patients with transplants from 1980 to 2014 from the Australia and New Zealand Dialysis and Transplant Registry. Using standardized mortality ratios (SMRs), we compared cancer mortality among patients on dialysis and patients with transplants versus the general population (overall and by age, sex, year, and site); we also performed a subgroup analysis excluding patients with preexisting cancers. RESULTS: We followed 52,936 patients on dialysis and 16,820 transplant recipients for 170,055 and 128,352 patient-years, respectively. There were 2739 cancer deaths among patients on dialysis and 923 cancer deaths among transplant recipients. Overall, cancer SMRs were 2.6 for patients on dialysis and 2.7 for transplant recipients. For patients on dialysis, SMRs were highest for multiple myeloma (30.5), testicular cancer (17.0), and kidney cancer (12.5); for transplant recipients, SMRs were highest for non-Hodgkin lymphoma (10.7), kidney cancer (7.8), and melanoma (5.8). Some 61.0% of patients on dialysis and 9.6% of transplant recipients who experienced cancer death had preexisting cancer. The SMRs for de novo cancer was 1.2 for patients on dialysis and 2.6 for transplant recipients. CONCLUSIONS: Patients on dialysis and transplant recipients experienced >2.5-fold increased risk of cancer death compared with the general population. This increased risk was largely driven by preexisting cancers in patients on dialysis and de novo cancers in patients with transplants.
Background Patients with ESRD have a substantially increased cancer risk, but few studies have examined the patterns of cancer mortality along a patient's journey from dialysis to transplantation. METHODS: We identified all Australian patients on dialysis and patients with transplants from 1980 to 2014 from the Australia and New Zealand Dialysis and Transplant Registry. Using standardized mortality ratios (SMRs), we compared cancer mortality among patients on dialysis and patients with transplants versus the general population (overall and by age, sex, year, and site); we also performed a subgroup analysis excluding patients with preexisting cancers. RESULTS: We followed 52,936 patients on dialysis and 16,820 transplant recipients for 170,055 and 128,352 patient-years, respectively. There were 2739 cancer deaths among patients on dialysis and 923 cancer deaths among transplant recipients. Overall, cancer SMRs were 2.6 for patients on dialysis and 2.7 for transplant recipients. For patients on dialysis, SMRs were highest for multiple myeloma (30.5), testicular cancer (17.0), and kidney cancer (12.5); for transplant recipients, SMRs were highest for non-Hodgkin lymphoma (10.7), kidney cancer (7.8), and melanoma (5.8). Some 61.0% of patients on dialysis and 9.6% of transplant recipients who experienced cancer death had preexisting cancer. The SMRs for de novo cancer was 1.2 for patients on dialysis and 2.6 for transplant recipients. CONCLUSIONS:Patients on dialysis and transplant recipients experienced >2.5-fold increased risk of cancer death compared with the general population. This increased risk was largely driven by preexisting cancers in patients on dialysis and de novo cancers in patients with transplants.
Authors: Claire M Vajdic; Stephen P McDonald; Margaret R E McCredie; Marina T van Leeuwen; John H Stewart; Matthew Law; Jeremy R Chapman; Angela C Webster; John M Kaldor; Andrew E Grulich Journal: JAMA Date: 2006-12-20 Impact factor: 56.272
Authors: P Maisonneuve; L Agodoa; R Gellert; J H Stewart; G Buccianti; A B Lowenfels; R A Wolfe; E Jones; A P Disney; D Briggs; M McCredie; P Boyle Journal: Lancet Date: 1999-07-10 Impact factor: 79.321
Authors: Angela C Webster; Rajah Supramaniam; Dianne L O'Connell; Jeremy R Chapman; Jonathan C Craig Journal: Nephrology (Carlton) Date: 2010-06 Impact factor: 2.506
Authors: John H Stewart; Claire M Vajdic; Marina T van Leeuwen; Janaki Amin; Angela C Webster; Jeremy R Chapman; Stephen P McDonald; Andrew E Grulich; Margaret R E McCredie Journal: Nephrol Dial Transplant Date: 2009-07-08 Impact factor: 5.992
Authors: Tracey Ying; Bree Shi; Patrick J Kelly; Helen Pilmore; Philip A Clayton; Steven J Chadban Journal: J Am Soc Nephrol Date: 2020-09-09 Impact factor: 10.121
Authors: Felix Becker; Anne-Sophie Mehdorn; Vasilios Getsopulos; Katharina Schütte-Nütgen; Stefan Reuter; Barbara Suwelack; Andreas Pascher; Jens G Brockmann; Ralf Bahde Journal: J Clin Med Date: 2021-05-27 Impact factor: 4.241
Authors: Camilo G Sotomayor; Ramón Rodrigo; António W Gomes-Neto; Juan Guillermo Gormaz; Robert A Pol; Isidor Minović; Manfred L Eggersdorfer; Michel Vos; Ineke J Riphagen; Martin H de Borst; Ilja M Nolte; Stefan P Berger; Gerjan J Navis; Stephan J L Bakker Journal: Nutrients Date: 2019-11-19 Impact factor: 5.717